Physician profile
Christopher Michael Cutshall
NPI 1649438052
$5,452.19
in general payments reported to CMS, 2019-2025
38 companies · $954 in 2025
The $954 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $208 · 2021: $280 · 2022: $849 · 2023: $1,458 · 2024: $1,290 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,701.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $851.84 | 2021-2025 | Linzess, Vraylar, Ubrelvy |
| Pfizer INC. | $666.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $556.96 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $498.64 | 2019-2025 | Evenity, Repatha, Otezla |
| Dexcom, INC. | $407.94 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $336.58 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $283.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $227.40 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $202.39 | 2021-2025 | |
| Astellas Pharma US INC | $152.34 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $139.96 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.59 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $104.20 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $103.18 | 2022-2024 | |
| Eisai INC. | $75.06 | 2021-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cutshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.